NEW YORK, Nov. 24, 2021 /PRNewswire/ -- WeissLaw LLP, a national shareholders' rights law firm, is investigating possible false claims, accounting and reporting practices and breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of CareDx, Inc. (NASDAQ: CDNA) ("CareDx" or the "Company"), which has led to investigations by the U.S. Department of Justice ("DOJ") and the Securities and Exchange Commission ("SEC") concerning "certain business practices related to [CareDx's] kidney testing and phlebotomy services."
If you own CareDx shares and wish to discuss this investigation, or share information which you have, or if you have any questions concerning this notice or your rights or interests, visit our website at
https://www.weisslaw.co/news-and-cases/cdna
Or please contact:
Josh Rubin, Esq
[email protected]
(212) 682-3025.
There is no cost or obligation to you.
On October 28, 2021, the Company filed a Form 10Q which disclosed that it had recently received a False Claims Act ("FCA") civil investigative demand from the DOJ as well as a subpoena from the SEC related to the Company's kidney testing and phlebotomy services "as well as certain of [CareDx's] accounting and public reporting practices." The Company also disclosed that an additional unnamed state regulatory agency has also made an information request, and it is possible that the Company will "receive additional requests for information...
The Department of Justice has charged over 450 people in health care fraud schemes totaling a record $6.5 billion. A Coos Bay man was charged with conspiracy to commit health care fraud in connect...